CN103655910A - Application of compound thrombosis capsule inn aspect of liver protection - Google Patents
Application of compound thrombosis capsule inn aspect of liver protection Download PDFInfo
- Publication number
- CN103655910A CN103655910A CN201310715689.1A CN201310715689A CN103655910A CN 103655910 A CN103655910 A CN 103655910A CN 201310715689 A CN201310715689 A CN 201310715689A CN 103655910 A CN103655910 A CN 103655910A
- Authority
- CN
- China
- Prior art keywords
- liver
- fufang xueshuantong
- xueshuantong jiaonang
- group
- thrombosis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Abstract
The invention is applicable to the field of Chinese patent medicines. A lipopolysaccharide-induced rat diffuse intravascular coagulation model is adopted for experimenting, and the experiment result shows that a compound thrombosis capsule can significantly inhibit the rise of liver-function biochemical indexes of aspartate aminotransferase and alanine aminotransferase, reduces the level of lipopolysaccharide-induced liver inflammation, and reduces congestion and hemorrhage phenomena in liver veins, namely finding out the new application of the compound thrombosis capsule playing a role of protecting the liver.
Description
Technical field
The invention belongs to technical field of Chinese patent medicine, relate in particular to the purposes of FUFANG XUESHUANTONG JIAONANG aspect the liver protecting.
Background technology
Cardiovascular and cerebrovascular disease has become one of disease that global mortality rate is the highest, and the sickness rate of China's cardiovascular and cerebrovascular disease is also constantly soaring.Because liver is the maincenter of sugar, fat, protein three large substance metabolismes, lipid metabolism can cause hyperlipemia extremely, and the gallbladder in blood is admittedly liquor-saturated to be increased with triglyceride, easily atherogenicity.Therefore, liver function is normally whether in close relations with cardiovascular disease.And, the main place that in liver cell or human body, multiple thrombin generates, the balance of human body intravascular coagulation and fibrinolytic also needs the normal performance of liver function.In addition, existence due to multiple risk factors in cardiovascular and cerebrovascular disease, in treatment, often adopt at present the medication combined and long-term taking of the different mechanism of action such as blood fat reducing, blood pressure lowering, and the hepar damnification that Long-term taking medicine causes also becomes the problem can not be ignored in cardiovascular treatment.Therefore, the liver protecting research in cardiovascular and cerebrovascular diseases seems very important, and liver function protecting has protected people's Source of life.
First is used for the treatment of the oral Chinese medicine of optical fundus blood vessel disease and cardiovascular and cerebrovascular disease China of the common development of FUFANG XUESHUANTONG JIAONANG Shi You Zhongshan University Eye Center and Guangdong Zhongsheng Pharmaceutical Co., Ltd, the compound Chinese patent medicine preparation being formed by Radix Notoginseng, Radix Salviae Miltiorrhizae, the Radix Astragali, Radix Scrophulariae four Chinese medicine, there is blood circulation promoting and blood stasis dispelling, the effect of supplementing QI and nourishing YIN, principal indication is the hold concurrently retinal vein occlusion and the stability angina of effort of syndrome of deficiency of both qi and yin of blood stasis, relates to the treatment in the fields such as fundus oculi disease, cardiovascular and cerebrovascular vessel, nephropathy, nervous system disease simultaneously.FUFANG XUESHUANTONG JIAONANG is protected kind as national secondary Chinese medicine, national emphasis new product, and after listing in 1996, clinical application effect is remarkable, in doctor and patient, has formed public's praise, has brought huge society and economic benefit.
Summary of the invention
The object of the invention is to: the purposes of FUFANG XUESHUANTONG JIAONANG aspect the liver protecting is provided, is intended to solve the liver protecting problem in cardiovascular and cerebrovascular diseases.
The object of the present invention is achieved like this:
The purposes of FUFANG XUESHUANTONG JIAONANG aspect the liver protecting,
Outstanding advantages of the present invention is: the present invention is by adopting lipopolysaccharide-induced rat disseminated inravascular coagulation model to test; find that FUFANG XUESHUANTONG JIAONANG can significantly suppress the rising of liver function biochemical indicator aspartate aminotransferase, alanine aminotransferase; reduce lipopolysaccharide-induced inflammation level; reduce congestion and bleeding in hepatic vein, find that FUFANG XUESHUANTONG JIAONANG has this new purposes of protective effect to liver.
Accompanying drawing explanation
Fig. 1 is the experimental result block diagram of the FUFANG XUESHUANTONG JIAONANG that provides of the embodiment of the present invention to liver function index ALT in serum;
Fig. 2 is the experimental result block diagram of the FUFANG XUESHUANTONG JIAONANG that provides of the embodiment of the present invention to liver function index AST in serum;
Fig. 3 is the experimental result picture of the FUFANG XUESHUANTONG JIAONANG that provides of the embodiment of the present invention to liver organization pathology.
The specific embodiment
In order to make object of the present invention, technical scheme and advantage clearer, below in conjunction with drawings and Examples, the present invention is further elaborated.Should be appreciated that specific embodiment described herein, only in order to explain the present invention, is not intended to limit the present invention.
The present invention is by adopting lipopolysaccharide-induced rat disseminated inravascular coagulation model to test; find that FUFANG XUESHUANTONG JIAONANG can significantly suppress the rising of liver function biochemical indicator aspartate aminotransferase, alanine aminotransferase; reduce lipopolysaccharide-induced inflammation level; reduce congestion and bleeding in hepatic vein, find that FUFANG XUESHUANTONG JIAONANG has this new purposes of protective effect to liver.
Below in conjunction with specific experiment, FUFANG XUESHUANTONG JIAONANG is described further in the new purposes aspect the liver protecting.
1. laboratory animal:
SD rat, SPF level, male, body weight 150～200 g, are provided by Guangdong Medical Lab Animal Center, the animal quality certification number: SCXK(Guangdong) 2008-0002.
2. medicine grouping and processing:
Normal group: normal saline.
Model control group: adopt tail vein injection lipopolysaccharide to cause rat disseminated inravascular coagulation model, give equal-volume normal saline.
FUFANG XUESHUANTONG JIAONANG low dose group: get FUFANG XUESHUANTONG JIAONANG before experiment, adding normal saline, to be mixed with concentration be 38 mg/ml suspensions.
Dosage group in FUFANG XUESHUANTONG JIAONANG: get FUFANG XUESHUANTONG JIAONANG before experiment and add normal saline to be mixed with concentration be 76 mg/ml suspensions.
FUFANG XUESHUANTONG JIAONANG high dose group: get FUFANG XUESHUANTONG JIAONANG before experiment and add normal saline to be mixed with concentration be 152 mg/ml suspensions.
3. experimental technique:
Get SD rat and be divided at random 5 groups, be i.e. dosage group, FUFANG XUESHUANTONG JIAONANG high dose group in Normal group, model control group, positive drug control group, FUFANG XUESHUANTONG JIAONANG low dose group, FUFANG XUESHUANTONG JIAONANG, every group of 8 rats.Laboratory animal adapted to after one week in feeding environment, and once, administration volume is 10 mL/kg to FUFANG XUESHUANTONG JIAONANG group gastric infusion every day, successive administration 7 days.Normal group, model control group and positive drug control group gavage give same volume normal saline.In the 8th day early morning, after three dosage group gastric infusion 1h of FUFANG XUESHUANTONG JIAONANG, the LPS of tail vein injection 4 mg/kg manufactures rat DIC model.The normal saline of Normal group tail vein injection same volume, the LPS of positive controls tail vein injection 4 mg/kg after the heparin 1h of tail vein injection 500 IU/kg.
Each group is injected 10% chloral hydrate (0.35 mL/100 g) anesthesia at lps injection 4 h pneumoretroperitoneums, postcava blood sampling, after centrifugalize serum, application EOS-880 semi-automatic biochemical analyzer is measured the content of respectively organizing aspartate aminotransferase in serum (AST), alanine aminotransferase (ALT).Test kit builds up Bioengineering Research Institute by Nanjing and provides, and the method providing by test kit is measured.
After blood-letting, get immediately rat liver tissue, with 10% formaldehyde, fix after 24 hours,, paraffin embedding transparent through flowing water washing, gradient concentration 70%, 80%, 90%, 95% and anhydrous alcohol dehydration, dimethylbenzene, with cycle type microtome (LEI is with RMZ135 Germany), be cut into 4um and cut into slices, finally carry out hematoxylin Yihong (Hematoxylin mono-Eosin, HE) dyeing, in the pathologic structure of optical microphotograph Microscopic observation liver organization.
4. experimental result:
(1) impact of FUFANG XUESHUANTONG JIAONANG on liver function index ALT, AST in serum
Often adopt clinically ALT and AST as the index of liver function biochemical analysis.ALT is that alanine aminotransferase, AST are aspartate transaminase, and the two is mainly distributed in hepatocyte.After hepatocellular degeneration necrosis, transaminase can be disengaged and be entered blood, and serum AST, ALT are raise.
From table 1, Fig. 1 and Fig. 2, with Normal group comparison, in model group rat blood serum, ALT and AST significantly improve (P<0.01), illustrate that lipopolysaccharide has caused hepatocellular damage.In the basic, normal, high dosage group of FUFANG XUESHUANTONG JIAONANG rat blood serum, the level of ALT and AST is all than the remarkable reduction of model group, and difference all has statistical significance (P<0.01 or 0.05), and is dose-effect relationship.Illustrate that FUFANG XUESHUANTONG JIAONANG can suppress lipopolysaccharide-induced hepatocyte injury degree.Due to the synthetic multiple thrombin of liver, its function extremely will directly affect the balance of hemostatic system, the protective effect of FUFANG XUESHUANTONG JIAONANG to liver, can explain its effect to the whole regulation and control of hemostatic system.
The impact () of table 1 FUFANG XUESHUANTONG JIAONANG on liver function index ALT, AST in serum
In Fig. 1 and 2, experimental group corresponding to each numeral is: 1-Normal group; 2-model control group; 3-positive drug control group (heparin, 500 IU/kg); 4-FUFANG XUESHUANTONG JIAONANG low dose group (380 mg/kg); Dosage group in 5-FUFANG XUESHUANTONG JIAONANG (760 mg/kg); 6-FUFANG XUESHUANTONG JIAONANG high dose group (1520 mg/kg).
(2) impact of FUFANG XUESHUANTONG JIAONANG on liver organization pathology
Experimental result as shown in Figure 3, a wherein: Normal group; B: model control group; C: positive drug control group (heparin, 500 IU/kg); D: FUFANG XUESHUANTONG JIAONANG low dose group (380 mg/kg); E: dosage group in FUFANG XUESHUANTONG JIAONANG (760 mg/kg); F: FUFANG XUESHUANTONG JIAONANG high dose group (1520 mg/kg).
As seen from Figure 3, blank group rat hepatocytes, centered by central vein, is radial arrangement to surrounding, the hepatocyte strand structure of formation rule.Model group rat is after tail vein injection LPS 4h, and central vein has obvious congestion, and has a large amount of inflammatory cells to exist; Between hepatic cords, the obvious dilatation and congestion in space, follows inflammatory cell infiltration; There is edema in hepatocyte, and has partial necrosis phenomenon.Positive drug heparin matched group can significantly improve the hepatic pathology of DIC rat, hepatic cords queueing discipline, though there is a small amount of inflammatory cell infiltration, without obvious congestion and bleeding.Three dosage groups of FUFANG XUESHUANTONG JIAONANG are compared with model group, and the hepatic pathology of DIC rat is all improved significantly, and in central vein, congestion significantly reduces, and best results under high dose.Without significantly congestion and bleeding, and hepatocyte structural arrangement is neat in FUFANG XUESHUANTONG JIAONANG high dose group central vein, and inflammatory cell infiltration reduces, and effect is suitable with positive drug heparin, is better than in FUFANG XUESHUANTONG JIAONANG, low dose group.
According to the result of above-mentioned pathological section, in conjunction with above-mentioned FUFANG XUESHUANTONG JIAONANG, to the improvement of liver function biochemical indicator, can find out, FUFANG XUESHUANTONG JIAONANG has good protective effect to the liver of DIC rat.Because liver function is brought into play important regulating action in blood coagulation and anticoagulant balance, FUFANG XUESHUANTONG JIAONANG has also explained that from body integral level FUFANG XUESHUANTONG JIAONANG brings into play antithrombotic mechanism to the protective effect of liver.
The foregoing is only preferred embodiment of the present invention, not in order to limit the present invention, all any modifications of doing within the spirit and principles in the present invention, be equal to and replace and improvement etc., within all should being included in protection scope of the present invention.
Claims (2)
1. the purposes of FUFANG XUESHUANTONG JIAONANG aspect the liver protecting.
2. the purposes of FUFANG XUESHUANTONG JIAONANG as claimed in claim 1 aspect the liver protecting; it is characterized in that; be specially FUFANG XUESHUANTONG JIAONANG in the rising that suppresses liver function biochemical indicator aspartate aminotransferase, alanine aminotransferase; reduce lipopolysaccharide-induced inflammation level, the congestion in minimizing hepatic vein and the purposes of hemorrhage aspect.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310715689.1A CN103655910B (en) | 2013-12-23 | 2013-12-23 | Application of compound thrombosis capsule inn aspect of liver protection |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310715689.1A CN103655910B (en) | 2013-12-23 | 2013-12-23 | Application of compound thrombosis capsule inn aspect of liver protection |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103655910A true CN103655910A (en) | 2014-03-26 |
| CN103655910B CN103655910B (en) | 2015-07-15 |
Family
ID=50295469
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310715689.1A Active CN103655910B (en) | 2013-12-23 | 2013-12-23 | Application of compound thrombosis capsule inn aspect of liver protection |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103655910B (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104523974A (en) * | 2014-12-31 | 2015-04-22 | 广东广发制药有限公司 | Traditional Chinese medicine preparation for preventing and treating hepatic fibrosis, soft capsule for preventing and treating hepatic fibrosis and preparing process of traditional Chinese medicine preparation and soft capsule |
| CN109771512A (en) * | 2019-01-24 | 2019-05-21 | 中山大学 | Compound Xueshuantong preparation purposes in preparing anti-inflammatory drugs |
| CN113559148A (en) * | 2020-04-29 | 2021-10-29 | 天士力医药集团股份有限公司 | Application of traditional Chinese medicine composition and preparation thereof in preparation of medicine for preventing and/or treating novel coronavirus pneumonia |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1425412A (en) * | 2002-12-17 | 2003-06-25 | 广东众生药业股份有限公司 | Compound oral thrombolytic preparation and its preparing method |
| WO2004050026A2 (en) * | 2002-12-02 | 2004-06-17 | Jiafang Chen | Compositions and methods for treating prostate cancer |
| JP2011087919A (en) * | 2010-09-06 | 2011-05-06 | Kao Corp | New method for diagnosing constitution and method for counselling using same |
-
2013
- 2013-12-23 CN CN201310715689.1A patent/CN103655910B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004050026A2 (en) * | 2002-12-02 | 2004-06-17 | Jiafang Chen | Compositions and methods for treating prostate cancer |
| CN1425412A (en) * | 2002-12-17 | 2003-06-25 | 广东众生药业股份有限公司 | Compound oral thrombolytic preparation and its preparing method |
| JP2011087919A (en) * | 2010-09-06 | 2011-05-06 | Kao Corp | New method for diagnosing constitution and method for counselling using same |
Non-Patent Citations (3)
| Title |
|---|
| 刘志新等: "复方血栓通对青年腹型肥胖患者血液流变学的作用", 《河北中医》 * |
| 刘杰: "复方血栓通胶囊对糖尿病肾病的疗效观察", 《中国优秀硕士学位论文全文数据库 医药卫生科技辑》 * |
| 张祯: "复方血栓通胶囊对早期糖尿病肾病患者血清炎性指标的影响", 《中国医药指南》 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104523974A (en) * | 2014-12-31 | 2015-04-22 | 广东广发制药有限公司 | Traditional Chinese medicine preparation for preventing and treating hepatic fibrosis, soft capsule for preventing and treating hepatic fibrosis and preparing process of traditional Chinese medicine preparation and soft capsule |
| CN109771512A (en) * | 2019-01-24 | 2019-05-21 | 中山大学 | Compound Xueshuantong preparation purposes in preparing anti-inflammatory drugs |
| CN113559148A (en) * | 2020-04-29 | 2021-10-29 | 天士力医药集团股份有限公司 | Application of traditional Chinese medicine composition and preparation thereof in preparation of medicine for preventing and/or treating novel coronavirus pneumonia |
| CN113559148B (en) * | 2020-04-29 | 2024-01-02 | 天士力医药集团股份有限公司 | Application of traditional Chinese medicine composition and preparation thereof in preparation of medicines for preventing and/or treating novel coronavirus pneumonia |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103655910B (en) | 2015-07-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Akchurin et al. | Update on inflammation in chronic kidney disease | |
| Wang et al. | The effects of Buyang Huanwu Decoction on hemorheological disorders and energy metabolism in rats with coronary heart disease | |
| US20210346281A1 (en) | Multi-component injection | |
| Liu et al. | Neferine inhibits proliferation and collagen synthesis induced by high glucose in cardiac fibroblasts and reduces cardiac fibrosis in diabetic mice | |
| CN101721488B (en) | Pharmaceutical composition for treating liver diseases and prepration method thereof | |
| CN104705258A (en) | Construction method and application of diet-induced insulin resistance model | |
| CN103655910B (en) | Application of compound thrombosis capsule inn aspect of liver protection | |
| Li et al. | Effects of Shenfu injection in the treatment of septic shock patients: a multicenter, controlled, randomized, open-label trial | |
| Wang et al. | Effect of ethanol extract of Rhodiola rosea on the early nephropathy in type 2 diabetic rats | |
| Liu et al. | Superior effect of hypertonic saline over mannitol to attenuate cerebral edema in a rabbit bacterial meningitis model | |
| Xiping et al. | Effects of salvia miltiorrhizae on ICAM-1, TLR4, NF-κB and bax proteins expression in multiple organs of rats with severe acute pancreatitis or obstructive jaundice | |
| Shin et al. | Propofol intravenous anaesthesia with desflurane compared with desflurane alone on postoperative liver function after living-donor liver transplantation: a randomised controlled trial | |
| CN101112407A (en) | Application of chrysanthemum indicum extract in the preparation of medicine for preventing and curing alcoholic liver disease | |
| CN103816532A (en) | Application of recombinant ganoderma lucidum immunoregulatory protein (rLZ-8) in preparation of medicines for treating chronic cardiac failure | |
| Ding et al. | Qingchangligan formula alleviates acute liver injury by attenuating extracellular histone-associated inflammation | |
| CN104784192B (en) | The application of freshwater mussel meat oligosaccharides in hypoglycemic drug is prepared and preparation method thereof | |
| CN104645241B (en) | Application of the Chinese medicine composition in the drug for preparing treatment atherosclerosis | |
| CN103272122B (en) | Traditional Chinese medicinal composition for treating Chronic aplastic anemia | |
| CN103655909A (en) | Application of compound thrombosis capsule in aspect of kidney protection | |
| CN101461802A (en) | Application of epi-gallocatechin-3-gallate in preparing medicament for preventing and treating high-fat fatty liver | |
| CN104546697A (en) | Dexibuprofen injection drug composition and preparation method thereof | |
| Zeng et al. | Study on the protective mechanism of dexmedetomidine on the liver of perioperative diabetic patients: A randomized controlled trial | |
| Sun et al. | Effect of alloxan time administerDrug on establishing diabetic rabbit model | |
| CN102600376B (en) | Application of Gastrodia Elata Bl. and extract of Gastrodia Elata Bl. in preparation of medicine for treating and repairing peripheral nerve injury | |
| CN104758373A (en) | Application of shenkang injection to preparing medicine for treating hepatopathy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |